share_log

Goldman Sachs Initiates Coverage On RXO With Neutral Rating, Announces Price Target of $20

Benzinga Real-time News ·  Nov 22, 2022 22:02

Goldman Sachs analyst Jordan Alliger initiates coverage on RXO (NYSE:RXO) with a Neutral rating and announces Price Target of $20.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment